D. E. Shaw & Co., Inc. Trevena Inc Transaction History

D. E. Shaw & Co., Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$0.2 - $0.5 $103,601 - $259,003	-518,006 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$0.41 - $0.63 $112,524 - $172,903	274,450 Added 112.68%	518,006 $285,000
Q4 2021 Feb 14, 2022	BUY	$0.57 - $1.29 $138,826 - $314,187	243,556 New	243,556 $142,000
Q4 2019 Feb 14, 2020	SELL	$0.62 - $1.06 $9,530 - $16,293	-15,371 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$0.81 - $1.06 $18,248 - $23,880	-22,529 Reduced 59.44%	15,371 $15,000
Q2 2019 Aug 14, 2019	BUY	$0.94 - $1.6 $35,626 - $60,640	37,900 New	37,900 $39,000
Q4 2017 Feb 14, 2018	SELL	$1.4 - $2.6 $17,918 - $33,277	-12,799 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$2.22 - $2.79 $28,413 - $35,709	12,799	12,799 $33,000

Ticker TRVN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 173,680,992
Market Cap $273M
Description
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.